Lexicon to Acquire Drug Discoverer Coelacanth | GenomeWeb

NEW YORK, June 13 – Lexicon Genetics said Wednesday it would acquire Coelacanth in a deal valued at about $32 million, reflecting Lexicon's efforts to build its drug discovery capabilities.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

An opinion piece in the New York Times urges lawmakers to keep genetic protections in place.

Research funding in Canada is to remain mostly the same, ScienceInsider reports.

In Science this week: random DNA replication errors play role in cancer, and more.

The Bill and Melinda Gates Foundation embarks on an open-access publishing path.